ReCode Therapeutics to Present Preclinical Data Using Proprietary SORT LNP Delivery Platform From Its mRNA-based Therapeutic Programs at the ATS 2022 International Conference in San Francisco

MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)--ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its selective organ targeting (SORT) lipid nanoparticles (LNP) delivery platform, today announced that it will present preclinical data from its mRNA-based therapeutic programs in cystic fibrosis and primary ciliary dyskinesia at the American Thoracic Society’s ATS 2022 International Conference, taking place May 13-18, 2022 in San Francisco, California.

Poster Presentation Information

Poster Title: An mRNA-Based Therapy to Treat Primary Ciliary Dyskinesia: Aerosol Delivery, Biodistribution and Tolerability
Poster Number: P313
Session Title: A62 – Cystic Fibrosis and Non-CF Bronchiectasis: Mechanistic Insights
Date and Time: Sunday, May 15, 2022, 11:15 a.m. – 1:15 p.m. PT
Location: Area D, Hall F (North Building, Exhibition Level), Moscone Center
Presenter: Dave Liston, Principal Scientist, ReCode Therapeutics

Poster Title: Rescue of Ciliary Function in Cell-Based Primary Ciliary Dyskinesia Models Using Nebulized, Lipid Nanoparticle (LNP)-Formulated mRNA
Poster Number: P309
Session Title: A62 – Cystic Fibrosis and Non-CF Bronchiectasis: Mechanistic Insights
Date and Time: Sunday, May 15, 2022, 11:15 a.m. – 1:15 p.m. PT
Location: Area D, Hall F (North Building, Exhibition Level), Moscone Center
Presenter: Rumpa Bhattacharjee, Scientist II, ReCode Therapeutics

Poster Title: Optimization of DNAI1 mRNA Constructs to Treat Primary Ciliary Dyskinesia
Poster Number: P316
Session Title: A62 – Cystic Fibrosis and Non-CF Bronchiectasis: Mechanistic Insights
Date and Time: Sunday, May 15, 2022, 11:15 a.m. – 1:15 p.m. PT
Location: Area D, Hall F (North Building, Exhibition Level), Moscone Center
Presenter: Mirko Hennig, Principal Scientist, ReCode Therapeutics

Poster Title: Functional Rescue of CFTR by Aerosolized Delivery of Optimized CFTR mRNA Using ReCode-LNPs in Primary Human Bronchial Epithelial Cells Derived from Patients with Cystic Fibrosis
Poster Number: 705
Session Title: D109 – Airway of Interest: Epithelial and Smooth Muscle Function in Health and Disease
Date and Time: Wednesday, May 18, 2022, 12:45 – 2:15 p.m. PT
Location: Room 2009/2011 (West Building, Level 2), Moscone Center
Presenter: Daniella Ishimaru, Principal Scientist, ReCode Therapeutics

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.